Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Previous studies suggested that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may initially worsen and possibly increase the risk of diabetic retinopathy. However, data on this possible association remain limited. Thus, this population-based study aimed to determine whether use of GLP-1 RAs is associated with an increased risk of incident diabetic retinopathy. RESEARCH DESIGN AND METHODS: Using the U.K. Clinical Practice Research Datalink (CPRD), we conducted a cohort study among 77,115 patients with type 2 diabetes initiating antidiabetic drugs between January 2007 and September 2015. Adjusted hazard ratios (HRs) and 95% CIs of incident diabetic retinopathy were estimated using time-dependent Cox proportional hazards models, comparing use of GLP-1 RAs with current use of two or more oral antidiabetic drugs. In an ancillary analysis, new users of GLP-1 RAs were compared with new users of insulin. RESULTS: During 245,825 person-years of follow-up, 10,763 patients were newly diagnosed with diabetic retinopathy. Compared with current use of two or more oral antidiabetic drugs, use of GLP-1 RAs was not associated with an increased risk of incident diabetic retinopathy overall (HR 1.00, 95% CI 0.85–1.17). Compared with insulin, GLP-1 RAs were associated with a decreased risk of diabetic retinopathy (HR 0.67, 95% CI 0.51–0.90). CONCLUSIONS: The associations with diabetic retinopathy varied according to the type of comparator. When compared with use of two or more oral antidiabetic drugs, use of GLP-1 RAs was not associated with an increased risk of incident diabetic retinopathy. The apparent lower risk of diabetic retinopathy associated with GLP-1 RAs compared with insulin may be due to residual confounding.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several large real‐world studies have examined the association between GLP‐1RA and retinopathy, with apparently conflicting results in three recent large cohort studies, 115 , 118 , 119 leaving the question unsettled.”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [118]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290 · cited 1×
“We repeated the analyses to account for competing risk due to deaths from any cause (21).”
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationFlexible regression models with cubic splines
Durrleman, S., & Simon, R. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080504 · Cited by 2,689
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Cited by
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16364 · Cited by 207
Microvascular complications in diabetes: A growing concern for cardiologists
Avogaro, A., & Fadini, G. P. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.02.030 · Cited by 160
Gaborit, B., Julla, J.-B., Besbes, S., Proust, M., Vincentelli, C., Alos, B., Ancel, P., Alzaid, F., Garcia, R., Mailly, P., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz069 · Cited by 95
Ponirakis, G., Abdul‐Ghani, M. A., Jayyousi, A., Almuhannadi, H., Petropoulos, I. N., Khan, A., Gad, H., Migahid, O., Megahed, A., DeFronzo, R. A., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001420 · Cited by 83
Zheng, D., Li, N., Hou, R., Zhang, X., Wu, L., Sundquist, J., Sundquist, K., & Ji, J. (2023) · BMC Medicine · doi:10.1186/s12916-023-02753-6 · Cited by 74
Wang, F., Mao, Y., Wang, H., Liu, Y., & Huang, P. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01110-w · Cited by 78
Wai, K. M., Mishra, K., Koo, E., Ludwig, C. A., Parikh, R., Mruthyunjaya, P., & Rahimy, E. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.04.010 · Cited by 61
Protective Roles of Apigenin Against Cardiometabolic Diseases: A Systematic Review
Xu, Y., Li, X., & Wang, H. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.875826 · Cited by 70
Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management
Chun, J. H., & Butts, A. (2020) · JAAPA · doi:10.1097/01.jaa.0000669456.13763.bd · Cited by 45
Joo, J. H., Sharma, N., Shaia, J., Wu, A. K., Skugor, M., Singh, R. P., & Rachitskaya, A. V. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100547 · Cited by 37
“37 Furthermore, in observational and Mendelian randomization studies in 2390 diabetic patients from several Swedish Registers, Zheng et al buttressed the clinical fi nding of an inverse relationship between GLP-1RA use and DR with evidence of protective SNPs in the GLP1R gene.”
Simó, R., Franch‐Nadal, J., Vlacho, B., Real, J., Amado, E., Roux, J. A. F., Mata‐Cases, M., Ortega, E., Rigla, M., Vallés, J.-A., et al. (2023) · Diabetes Care · doi:10.2337/dc22-2521 · Cited by 42
Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
Mouhammad, Z. A., Vohra, R., Horwitz, A., Thein, A., Andreasen, J. R., Cvenkel, B., Williams, P. A., Azuara‐Blanco, A., & Kolko, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824054 · Cited by 35
El-Solh, A., Gould, E., Aibangbee, K. E., Jimerson, T., & Hartling, R. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2437525 · Cited by 34
“…complications was raised with semaglutide injection [72,73] but data obtained from Medicare beneficiaries did not substantiate this claim [74,75] although temporary worsening of retinopathy is a recognized phenomenon known to occur following rapid improvement in blood glucose in patients…”
Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review
Ntentakis, D. P., Correa, V., Ntentaki, A. M., Delavogia, E., Narimatsu, T., Efstathiou, N. E., & Vavvas, D. G. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06236-5 · Cited by 43
Hu, S., Su, X., & Fan, G. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01195-7 · Cited by 28
“However, in agreement with our findings, there are several studies reporting that no association between treatment with GLP-1RAs and AP or DR [55–57].”
ResultGravel, C. A., Krewski, D. R., Mattison, D. R., Momoli, F., & Douros, A. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15711 · Cited by 26
Self-citationUeda, P., Pasternak, B., Eliasson, B., Svensson, A., Franzén, S., Guðbjörnsdóttir, S., Hveem, K., Jonasson, C., Melbye, M., & Svanström, H. (2019) · Diabetes Care · doi:10.2337/dc18-2532 · Cited by 24
“studies on GLP-1 receptor agonists and diabetic retinopathy performed to date have excludedpatientswithahistoryof retinopathy (2) or treatment of retinopathy (3).”
BackgroundCaparrotta, T. M., Templeton, J. B., Clay, T. A., Wild, S. H., Reynolds, R. M., Webb, D. J., & Colhoun, H. M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01021-1 · Cited by 28
The State of Use and Utility of Negative Controls in Pharmacoepidemiologic Studies
Zafarí, Z., Park, J.-E., Shah, C. H., dosReis, S., Gorman, E. F., Hua, W., Ma, Y., & Tian, F. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad201 · Cited by 28
An update on ocular effects of antidiabetic medications
Sadeghi, E., Rahmanipour, E., Valsecchi, N., Kapoor, S., Cicinelli, M. V., & Chhablani, J. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.01.010 · Cited by 23
Górriz, J. L., Romera, I., Cobo, A., O’Brien, P. D., & Merino-Torres, J. F. (2022) · Diabetes Therapy · doi:10.1007/s13300-021-01198-5 · Cited by 31
“Conversely, population studies have found no association between increased risk of diabetic retinopathy and GLP-1 RA use [104, 105], with a low odds ratio observed for exenatide (OR 0.”
BackgroundMellor, J., Jeyam, A., Beulens, J. W. J., Bhandari, S., Broadhead, G., Chew, E. Y., Fickweiler, W., van der Heijden, A. A. W. A., Gordin, D., Simó, R., et al. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100494 · Cited by 25
“In addition, several cohort studies 72,73 and meta-analyses 68,74 have shown that GLP-1RA did not increase the risk of development and progression of DRD.”
Kapoor, I., Sarvepalli, S. M., D’Alessio, D. A., & Hadziahmetovic, M. (2024) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.14445 · Cited by 24
“19,25 This is an explanation that has been observed with multiple medications, including GLP-1RA and insulin and has been documented in both type 1 and type 2 diabetes.”
InfluentialJiao, X., Peng, P., Zhang, Q., & Shen, Y. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01319-x · Cited by 23
“Moreover, in comparison with insulin, GLP-1RAs significantly reduced the risk of DR [54].”
Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes
Tesfaye, H., Paik, J. M., Roh, M., Htoo, P. T., Zakoul, H., Schmedt, N., Koeneman, L., Wexler, D. J., & Patorno, E. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.5219 · Cited by 20
Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
Wołos-Kłosowicz, K., Matuszewski, W., Rutkowska, J., Krankowska, K., & Bandurska-Stankiewicz, E. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206183 · Cited by 19
“Another study comparing incidence of DR in patients treated with GLP-1 RAs and other antidiabetic medications did not reveal an overall increased risk for GLP-1 RAs and a 33% reduction was demonstrated for GLP-1 RAs compared to insulin [49].”
BackgroundResultLi, J., Hung, Y.-T., Bair, H., Hsu, S., Hsu, C. Y., & Lin, C. (2023) · Scientific Reports · doi:10.1038/s41598-023-43893-2 · Cited by 19
“Treatment with GLP-1RAs has not been associated with an increased risk of incident DR and may reduce the risk of DR 0.67-fold relative to insulin 25 .”
InfluentialYen, F.-S., Wei, J. C.-C., Shih, Y.-H., Hung, Y.-T., Hsu, T.-J., Hsu, C.-C., & Hwu, C.-M. (2024) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103099 · Cited by 13
Jensen, J. H., Vestergaard, P., & Jensen, M. H. (2023) · Current Drug Safety · doi:10.2174/1574886318666230420084701 · Cited by 13
Talebi, R., Fortes, B. H., Yu, F., Coleman, A. L., & Tsui, I. (2025) · Retina · doi:10.1097/iae.0000000000004507 · Cited by 15
McLaughlin, S. A., Davila, N., Shields, C., Bineshfar, N., Banaee, T., & Williams, B. K. (2025) · Retina · doi:10.1097/iae.0000000000004616 · Cited by 14
Luo, Y., Xia, Y., Gong, X., Hao, M., Wei, Q., & Liao, L. (2026) · BMC Ophthalmology · doi:10.1186/s12886-025-04559-x · Cited by 18
Igweokpala, S., Sule, N., Douros, A., Yu, O. H. Y., & Filion, K. B. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15367 · Cited by 14
“28, 31 –”
BackgroundSelf-citationPhu, A., Banghart, M., Bahrainian, M., Liu, T. Y. A., Wolf, R. M., & Channa, R. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108808 · Cited by 11
Incretin-based therapy: a new horizon in diabetes management
Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 13
“On the other hand, no association between GLP-1RA exposure and severe diabetic retinopathy has been reported by several studies [ 175 , 215 , 218 , 220 –223 ], even among patients with pre-existing ocular disease [224 ].”
Singh, H., Natt, N. K., & Nim, D. K. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2459720 · Cited by 10
“However, when compared to insulin, GLP-1 receptor agonists were associated with a lower risk of DR (HR 0.67, 95% CI 0.51–0.90) [9 ].”
InfluentialHuang, Y., Chen, J.-C., Li, P., Hsu, M., Cheng, C., Meyerowitz‐Katz, G., & Su, P. (2025) · Communications Medicine · doi:10.1038/s43856-025-01066-4 · Cited by 11
“Based on the supplemental subgroup analyses, several notable patterns emergedregardingtheassociationsbetweenTirzepatideandSemaglutidevstraditionalanti-obesitymedicationsacrossdifferentpatientcharacteristics andclinicalcontexts(SupplementaryData5 – 22).”
Addressing the risk of ocular complications of GLP ‐ 1RAs ; a multi‐disciplinary expert consensus
Carter, P., Simó, R., Lövestam‐Adrian, M., Pearce, I., Bain, S. C., Dinah, C., Davies, S. J., Strain, W. D., Burgess, P. I., Gamble, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70160 · Cited by 16
“10 Furthermore, a post-approval pharmacovigilance report found the frequency of retinal adverse events to be significantly lower with GLP-1RAs as compared with other glucose lowering medications.”
Evaluating the Effect of Hypoglycemic Agents on Diabetic Retinopathy Progression
Wai, K. M., Saroj, N., Boucher, N., Aggarwal, N., Ho, A. C., & Rahimy, E. (2023) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20230217-02 · Cited by 10
Semaglutide and diabetic retinopathy: an OHDSI network study
Cai, C. X., Nishimura, A., Baxter, S. L., Goetz, K., Hribar, M. R., Toy, B. C., Barkmeier, A. J., Wang, S. Y., Swaminathan, S. S., Flowers, A. M., et al. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005424 · Cited by 12
Variations in Electronic Health Record-Based Definitions of Diabetic Retinopathy Cohorts
Chen, J., Copado, I. A., Vallejos, C., Kalaw, F. G. P., Soe, P., Cai, C. X., Toy, B. C., Borkar, D. S., Sun, C. Q., Shantha, J. G., et al. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100468 · Cited by 8
Chen, T., Zhou, L., Wang, K., Ma, X., Wu, H., Liu, X., Tong, J., Cai, B., & Ji, Q. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.06.006 · Cited by 7
Shepard, B. D., & ECELBARGER, C. A. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.06.005 · Cited by 7
Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes
Hong, A. T., Lin, F., Keenan, J. D., & Stewart, J. M. (2026) · Ophthalmology Retina · doi:10.1016/j.oret.2026.02.002 · Cited by 7
Nielsen, T. A., Šega, R., Andersen, C. U., Vorum, H., Drewes, A. M., Jakobsen, P. E., Brock, B., & Brock, C. (2021) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2021.0055 · Cited by 5
“9 As for the long-term effects of semaglutide, an ongoing clinical trial (FOCUS trial) aims to evaluate these.”
Retinopathy risk factors in patients with type 2 diabetes on liraglutide
Mahzari, M. M., Alanazy, A. M., Feroz, Z., Almani, K. M., Alghamdi, M. A., Almadani, A. S., Alzahrani, M. K., Alibrahim, A. R., & Badri, M. (2024) · Medicine · doi:10.1097/md.0000000000039026 · Cited by 5
“[10] In conclusion, we found that the majority of patients with T2D who received liraglutide experienced an improvement or no change in their retinopathy status.”
BackgroundInfluentialQian, W., Liu, F., & Yang, Q. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13502 · Cited by 7
Alwafi, H. H., Alharbi, S. S., Al-adwani, G. A., Alsanosi, S., Oyelade, T., Almalki, F., Thalib, H. I., Naser, A. Y., Alfahmi, M. Z., Alotaibi, B. J., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1639704 · Cited by 10
“The association between the progression of diabetic retinopathy (DR) and GLP-1 receptor agonist (GLP-1RA) use is based on the presence of GLP-1 receptors on the retina.”
InfluentialGlucagon-like peptide-1 receptor agonists: What ophthalmologists need to know
Bala, S., Allan, K. C., Decker, N. L., Abbass, N. J., Joo, J. H., Zhao, A., Talcott, K. E., & Rachitskaya, A. V. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.12.007 · Cited by 7
Nonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People
Sood, A., & Swislocki, A. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0134 · Cited by 4
“129 Douros et al. 130 studied a cohort from U.K. Clinical Practice Research Datalink retrospectively and concluded that compared with oral antidiabetic drugs, use of GLP-1 was not associated with an increased risk of incident diabetic retinopathy.”
Vujosevic, S., Toma, C., Ferrulli, A., Cillà, S. D., Nucci, P., & Luzi, L. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02552-w · Cited by 6
Shen, B., Wang, W., Guo, Y., Chen, Z., Liu, C., Huang, J., & Li, Y. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01878-3 · Cited by 5
“Overall, a total of two studies reported a clear negative association between GLP-1RA and DR [27, 28].”
Comprehensive Factors for Predicting the Complications of Diabetes Mellitus: A Systematic Review
Erandathi, M., Wang, W. Y. C., Mayo, M., & Lee, C. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998271863231116062601 · Cited by 8
“Elevated DBP is linked to higher rates of kidney function decline in diabetic kidney disease [41-43, 53, 54, 59].”
BackgroundMethodInfluentialUses and Abuses of Big Data in Ophthalmology Research
Lee, C. S. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.02.018 · Cited by 2
Huang, J. X. F., Wu, J., Ahmad, H., Li, J., Joshi, S., Yousaf, A., Pemminati, R., & Pemminati, S. (2026) · Cureus · doi:10.7759/cureus.103234 · Cited by 3
“Notably, the authors highlighted a significant transient increase in DR risk during 6.1-12 months of GLP-1RA usage (HR 1.44, 95% CI 1.06-1.95), which eventually normalized after a year [34].”
InfluentialBeyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists
Lixi, F., Troisi, M., Calabresi, V., Giagoni, A., Rossi, C., Timofte-Zorila, M.-M., Tarași, T.-C., Vitiello, L., Tomi, M.-I., Gheorghe, A. G., et al. (2026) · Vision · doi:10.3390/vision10020029 · Cited by 2
Katamine, A., Oya, J., Kondo, Y., Hasegawa, Y., & Nakagami, T. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70407 · Cited by 1
“However, GLP-1 RAs have not been associated with an increased risk of incident diabetic retinopathy compared to other antidiabetic drugs 5 .”
Aggravation précoce de la rétinopathie diabétique lors de l’optimisation du contrôle glycémique
Feldman-Billard, S. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30150-0 · Cited by 1
Anatriello, A., Liguori, V., Cagnotta, C., Pentella, C., Scavone, C., Capuano, A., & Rinaldi, B. (2026) · Frontiers in pharmacology · doi:10.3389/fphar.2026.1808359 · Cited by 3
Diabetic retinopathy: a tool for cardiovascular risk stratification
Avogaro, A., & Fadini, G. P. (2020) · Diabetes Mellitus · doi:10.14341/dm10372
Perioperative Management of Diabetic Macular Edema
Leung, E. H., & Leung, J. H. (2020) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000320
Pharmacotherapy of diabetic retinopathy
Luthert, P. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-819291-7.00018-6
Nouveaux traitements du diabète de type 2 et rétinopathie diabétique
Feldman-Billard, S., & Halimi, S. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.08.007 · Cited by 1
Glucagon-like Peptide-1 Receptor Agonist for Diabetic Retinopathy: Friend or Foe?
Huiwen, T., Yuke, L., & Cholekho, S. (2023) · JOJ Ophthalmology · doi:10.19080/jojo.2023.10.555789
Lan, N., Liang, X., Li, Y., Han, L., Ou, H., Luo, Z., Li, J., Lin, Y., & Zhang, X. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5364609
Zheng, D., Li, N., Hou, R., Zhang, X., Wu, L., Sundquist, J., Sundquist, K., & Ji, J. (2023) · Figshare · doi:10.6084/m9.figshare.22598999
Semaglutide and the Effects of Glucagon-like Peptide-1 on Vision
Rajput, R., Chakravarti, H. N., Kesavadev, J., KOVIL, R. R., & Rajput, S. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_28_25
Diabetic Retinopathy Risk in SGLT2i vs GLP1RA Initiators With CKD Stages 3-4 and Type 2 Diabetes
Hansrivijit, P., Patorno, E., Tesfaye, H., Wexler, D. J., Roh, M., & Paik, J. M. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101518
Ong, T. Y. Y., Ng, N. C., Cheng, M. H., Ming, L. C., & Goh, B. H. (2026) · Current Ophthalmology Reports · doi:10.1007/s40135-026-00357-w
“Abbreviations : AMD, age-related macular degeneration; DME, diabetic macular edema; DR, diabetic retinopathy; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; nAMD, neovascular age-related macular degeneration; T2DM, type 2 diabetes mel - litus; VEGF, vascular endothelial growth factor 1…”
Influential
Metadata
- Authors
- Douros, A., Filion, K. B., Yin, H., Yu, O. H., Etminan, M., Udell, J. A., & Azoulay, L.
- Affiliations
- Jewish General Hospital (CA)
- University of British Columbia (CA)
- University of Toronto (CA)
- Corresponding author
- Azoulay, Laurent
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-08-27
- Volume
- 41
- Issue
- 11
- Pages
- 2330-2338
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2889059090
- Cited by
- 70
- References
- 35
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 12 · 2023: 14 · 2022: 6 · 2021: 5 · 2020: 5 · 2019: 4 · 2018: 1
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Heart and Stroke Foundation of Canada
- McGill University
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, diabetic retinopathy, type 2 diabetes, insulin, oral antidiabetic drugs, residual confounding, antidiabetic drug safety
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Middle Aged, Retrospective Studies, Risk Factors, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.